Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Since Hedin's characterization of trypsin and antitrypsin in 1906,(1) arguably the first
account of a regulatory protein–protein interaction (PPI), contemporary understanding of …

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has
been highly pursued by many academic laboratories and pharmaceutical companies as a …

Abstract Blocking the MDM2/X–P53 protein–protein interaction has been widely recognized
as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule …

Here, a redox-neutral palladium-catalyzed photo-induced radical cascade domino Heck
reaction of N-aryl acrylamide with vinyl arenes is described. A diverse range of bioactive …

Scaffold modification based on Wang's pioneering MDM2–p53 inhibitors led to novel,
chemically stable spiro-oxindole compounds bearing a spiro [3 H-indole-3, 2′-pyrrolidin]-2 …

Despite the achieved progress in developing efficient MDM2-p53 protein-protein interaction
inhibitors (MDM2 inhibitors), the acquired resistance of tumor cells to such p53 activators …

A recent therapeutic strategy in oncology is based on blocking the protein–protein
interaction between the murine double minute (MDM) homologues MDM2/X and the tumor …

Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small
molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe …

The tumor suppressor p53 plays a central role in anti-tumorigenesis and cancer therapy. It
has been described as “the guardian of the genome”, because it is essential for conserving …